Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 5/20 | 0.60 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 14/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.60 |
| ▸ | PGR | P06401 | 5/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.60 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.60 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.60 |
| ▸ | AR | P10275 | 2/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.60 |
| ▸ | TNF | P01375 | 1/20 | 0.60 |
| ▸ | IL6 | P05231 | 1/20 | 0.60 |
| ▸ | GLUL | P15104 | 1/20 | 0.60 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.60 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL945988 | 0.95 | HIF1A (0.65) | HIF1ALMNAHSD17B10NR3C1PGR | |
| SCHEMBL264554 | 0.94 | HIF1A (0.64) | HIF1ALMNAHSD17B10NR3C1PGR | |
| SCHEMBL27748218 | 0.92 | HIF1A (0.61) | HIF1ALMNAHSD17B10NR3C1PGR | |
| SCHEMBL7095395 | 0.92 | HIF1A (0.61) | HIF1ALMNAHSD17B10NR3C1PGR | |
| SCHEMBL704875 | 0.91 | HIF1A (0.61) | HIF1ALMNAHSD17B10NR3C1PGR | |
| SCHEMBL11068491 | 0.91 | HIF1A (0.62) | HIF1ALMNAHSD17B10NR3C1PGR | |
| SCHEMBL27781029 | 0.91 | HIF1A (0.66) | HIF1ALMNAHSD17B10NR3C1PGR | |
| SCHEMBL677626 | 0.91 | HIF1A (0.61) | HIF1ALMNAHSD17B10NR3C1PGR | |
| SCHEMBL22042713 | 0.90 | HIF1A (0.59) | HIF1ALMNAHSD17B10NR3C1PGR | |
| SCHEMBL35449 | 0.90 | HIF1A (0.64) | HIF1ALMNAHSD17B10NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1915 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4580674-A2 | ANTIGEN BINDING MOLECULES TARGETING PROGRAMMED CELL DEATH PROTEIN 1 (PD-1) | Flagship Pioneering Innovations VI, LLC (US) | 2025-07-09 | — | — | EP | claimed |
| EP-4567037-A1 | USE OF PYRROLOPYRIMIDINE COMPOUND IN TREATMENT OF ACUTE GRAFT VERSUS HOST DISEASE | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2025-06-11 | — | — | EP | claimed |
| CN-119585277-A | Use of pyrrolopyrimidine compounds for the treatment of acute graft versus host disease | 正大天晴药业集团股份有限公司 | 2025-03-07 | — | — | CN | claimed |
| CN-118501322-B | Method for detecting prednisolone sodium succinate related substances for injection | 成都启晟合研医药科技有限公司 | 2024-09-24 | — | — | CN | claimed |
| EP-4431097-A1 | USE OF QUINOLINONE DERIVATIVE IN TREATMENT OF IMMUNE THROMBOCYTOPENIA | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2024-09-18 | — | — | EP | claimed |
| US-20240285635-A1 | USE OF PYRROLOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATING CHRONIC GRAFT VERSUS HOST DISEASE | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-08-29 | — | — | US | claimed |
| CN-118501322-A | Method for detecting prednisolone sodium succinate related substances for injection | 成都启晟合研医药科技有限公司 | 2024-08-16 | — | — | CN | claimed |
| CN-118159269-A | Application of quinolinone derivative in treatment of immune thrombocytopenia | 正大天晴药业集团股份有限公司 | 2024-06-07 | — | — | CN | claimed |
| EP-4361152-A1 | USE OF PYRROLOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATING CHRONIC GRAFT VERSUS HOST DISEASE | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-05-01 | — | — | EP | claimed |
| WO-2024050421-A2 | ANTIGEN BINDING MOLECULES TARGETING PROGRAMMED CELL DEATH PROTEIN 1 (PD-1) | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2024-03-07 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| WO-1997041144-A1 | NOVEL STEROID NITRITE AND NITRATE ESTER DERIVATIVES USEFUL AS ANTI-INFLAMMATORY DRUGS | G.D. SEARLE & CO. (US) | 1997-11-06 | — | — | WO | claimed |
| EP-0792371-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-09-03 | — | — | EP | claimed |
| EP-0786999-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-08-06 | — | — | EP | claimed |
| WO-1997015298-A1 | COMBINATION OF LTD, RECEPTOR ANTAGONISTS WITH GLUCOCORTICOSTEROIDS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-05-01 | — | — | WO | claimed |
| US-5543417-A | 5 Alpha-reductase inhibitor and at least one of an antibacterial agent, a keratolytic agent or an anti-inflammatory agent | MERCK & CO., INC. (US) | 1996-08-06 | — | — | US | claimed |
| WO-1996012487-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| WO-1996012817-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| EP-0496520-A1 | Novel bone acting agents | MERCK & CO. INC. (US) | 1992-07-29 | — | — | EP | claimed |
| US-4304765-A | Ocular insert housing steroid in two different therapeutic forms | ALZA CORPORATION (US) | 1981-12-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240285635-A1 | USE OF PYRROLOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATING CHRONIC GRAFT VERSUS HOST DISEASE | TPMT, PTPN5, FKBP5 | NR3C1 600/4885PDE4D 473/4885HIF1A 3090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.